MAFG and prostate carcinoma: MAFG-AS1 expression is aberrant in diverse diseases, including breast cancer [43–49], lung cancer [50–52], liver cancer [53–58], bladder cancer [59–63], colorectal cancer [64–66], gastric cancer [67, 68], esophagus cancer [69], prostate cancer [70], pancreatic cancer [71], ovarian cancer [72], glioma [73], periodontitis [74], and coronary artery disease [75].